NCT00308633 is a clinical trial in Coronary Artery Disease (CAD), sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT00308633?

NCT00308633 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What condition does NCT00308633 study?

NCT00308633 studies Coronary Artery Disease (CAD).

Is NCT00308633 still recruiting?

NCT00308633 is currently completed. Last updated 2 July 2017.

Last reviewed 2017-07-02 · How we verify

NCT00308633

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants

Completed Last updated 2 July 2017

What this trial tests

trial in Coronary Artery Disease (CAD) in 55 participants. Completed.

Timeline

23 March 2006

Primary endpoint
28 December 2007

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	55
Start date	23 March 2006
Primary completion	28 December 2007
Sites	2 locations across United States

Conditions studied

Coronary Artery Disease (CAD) — all drugs for Coronary Artery Disease (CAD) →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

21 and older, any sex, with Coronary Artery Disease (CAD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will measure blood levels of endothelial progenitor cells (EPCs) and nitric oxide (NO) in patients with coronary artery disease (CAD) who are participating in a 3-month cardiac rehabilitation program at Suburban Hospital in Bethesda, MD. EPCs are a kind of stem cell produced by the bone marrow that can develop into cells found in arteries and in the heart and, therefore, can repair diseased vessels. The study will examine whether the EPCs are affected by exercise and will look at how they may contribute to repair of cells lining the diseased arteries as a result of participation in the rehabilitation program. People with coronary artery disease may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood tests. CAD patients also to a treadmill exercise test. Volunteers' participation ends at the screening visit. The blood drawn at screening is used to identify EPC specific genes to compare with the EPC genes from patients with CAD. CAD patients participate in Suburban Hospital's cardiac rehabilitation program. The exercise portion of the program includes 36 sessions of about 60 minutes each, spaced over approximately 3 months. Patients have a baseline blood test at screening and repeat blood tests at the end of each month of participation in the rehabilitation program. Some of the blood will be used for genetic tests to see how genes of the EPCs are changed by the patient's participation in the rehabilitation program.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Engineering better stem cell therapies for treating heart diseases.
Li J, Hu S, Cheng K. · · 2020 · cited 11× · PMID 32775370 · DOI 10.21037/atm.2020.03.44
Mechanisms for progenitor cell-mediated repair for ischemic heart injury.
Li SC, Acevedo J, Wang L, Jiang H, et al · · 2012 · cited 8× · PMID 21466480 · DOI 10.2174/157488812798483449

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease (CAD)

Currently open trials in the same condition.

NCT07479433 — The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI · recruiting
NCT07349875 — Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial · Phase 4 · recruiting
NCT07277686 — AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population · recruiting
NCT07148518 — Comparison of Upper and Lower Limb Maximal Exercise Capacities and Arterial Stiffness in Patients With CAD · recruiting
NCT07392021 — Effects of a Recovery-Promoting Program in Patients Undergoing CABG Surgery · NA · active not recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00308633 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 2 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00308633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing